The Use of Machine Learning to Create a Risk Score to Predict Survival in Patients with Hepatocellular Carcinoma: A TCGA Cohort Analysis.
Journal
Canadian journal of gastroenterology & hepatology
ISSN: 2291-2797
Titre abrégé: Can J Gastroenterol Hepatol
Pays: Egypt
ID NLM: 101623613
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
08
2021
revised:
15
11
2021
accepted:
17
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver malignancies and is currently the fourth most common cause of cancer-related death worldwide. Due to varying underlying etiologies, the prognosis of HCC differs greatly among patients. It is important to develop ways to help stratify patients upon initial diagnosis to provide optimal treatment modalities and follow-up plans. The current study uses Artificial Neural Network (ANN) and Classification Tree Analysis (CTA) to create a gene signature score that can help predict survival in patients with HCC. The Cancer Genome Atlas (TCGA-LIHC) was analyzed for differentially expressed genes. Clinicopathological data were obtained from cBioPortal. ANN analysis of the 75 most significant genes predicting disease-free survival (DFS) was performed. Next, CTA results were used for creation of the scoring system. Cox regression was performed to identify the prognostic value of the scoring system. 363 patients diagnosed with HCC were analyzed in this study. ANN provided 15 genes with normalized importance >50%. CTA resulted in a set of three genes (NRM, STAG3, and SNHG20). Patients were then divided in to 4 groups based on the CTA tree cutoff values. The Kaplan-Meier analysis showed significantly reduced DFS in groups 1, 2, and 3 (median DFS: 29.7 months, 16.1 months, and 11.7 months, Long-term outcomes of patients with HCC can be predicted using a simplified scoring system based on tumor mRNA gene expression levels. This tool could assist clinicians and researchers in identifying patients at increased risks for recurrence to tailor specific treatment and follow-up strategies for individual patients.
Identifiants
pubmed: 34888264
doi: 10.1155/2021/5212953
pmc: PMC8651371
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell Cycle Proteins
0
STAG3 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5212953Subventions
Organisme : NCI NIH HHS
ID : T32 CA113263
Pays : United States
Informations de copyright
Copyright © 2021 Samer Tohme et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
World J Gastroenterol. 2020 Jul 14;26(26):3720-3736
pubmed: 32774053
Mol Clin Oncol. 2013 Jul;1(4):593-598
pubmed: 24649215
PLoS Genet. 2014 Jul 03;10(7):e1004413
pubmed: 24992337
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Front Genet. 2020 Oct 20;11:522125
pubmed: 33193605
Biomed Pharmacother. 2017 May;89:857-863
pubmed: 28282787
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2495-2503
pubmed: 32238405
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
J Transl Med. 2020 Feb 11;18(1):67
pubmed: 32046766
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
HPB (Oxford). 2021 Feb;23(2):309-320
pubmed: 32811764
Curr Mol Med. 2012 Dec;12(10):1372-82
pubmed: 23092226
Psychol Aging. 2015 Dec;30(4):911-29
pubmed: 26389526
Cells. 2020 Jun 01;9(6):
pubmed: 32492896
Sci Rep. 2020 Jul 7;10(1):11124
pubmed: 32636408
Exp Mol Med. 2020 Dec;52(12):1898-1907
pubmed: 33268834
Clin Liver Dis. 2020 Nov;24(4):535-547
pubmed: 33012444
Gut. 2016 May;65(5):861-9
pubmed: 25666192
Lancet Oncol. 2016 Feb;17(2):e81-e86
pubmed: 26868357
Oncol Lett. 2019 Jan;17(1):951-957
pubmed: 30655853
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Med. 2016 Sep;22(9):1056-61
pubmed: 27500726
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Clin Oncol. 2004 Jun 15;22(12):2284-93
pubmed: 15136595
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Cancer. 2018 Sep 1;124(17):3551-3559
pubmed: 30113700
Sci Rep. 2017 Jul 17;7(1):5517
pubmed: 28717245